Foundayo (orforglipron) is Eli Lilly's small-molecule oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related condition
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
The brand's disclaimer on its own website acknowledges this directly: "results can vary from person to person," and "some names and personally identifying information on this site have been changed to protect individuals' privacy." That last disclosure is important - it confirms that some testimonials on the brand's website may use modified identifying information
Podrczny sownik chemiczny , Romuald Hassa (red.), Janusz Mrzigod (red.), Janusz Nowakowski (red.), Katowice: Videograf II, 2004, s
B., Hellinger A., Griese E
PMID:29155147 Babula JJ, et al